BioSpace News Archive

Calviri, Inc. announced the successful conclusion of the Vaccine Against Canine Cancer Study on May 4, 2024; a five-year clinical trial investigating a novel preventative cancer vaccine in dogs.

Novo Nordisk launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don’t have to manage their weight alone.

Bristol Myers Squibb announced data from three studies evaluating Breyanzi®, including long-term data with three-year follow-up from the Phase 3 TRANSFORM trial of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma.

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for a broad range of immunological diseases and cancer, announced today that clinical data for its lead drug candidate, ELA026, will be presented as one of five selected abstracts in a late-breaking oral session at the European Hematology Association (EHA) Congress.

Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it has entered into a multi-target drug discovery collaboration with Merck KGaA, Darmstadt, Germany.

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based pharmaceutical technology, is pleased to announce the appointment of Dr. Douglas Gladue, PhD as the new Vice President of Veterinary Pharmaceutical Development.

BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.

Burning Rock Biotech Limited announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450.

Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of June:.

NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced promising interim results of its major clinical trial NIT-110 of NT-I7, at the 2024 American Society of Clinical Oncology global meeting held in Chicago, from May 31 to June 4.